Nasopharyngeal Airway Combined With Nasal High-flow Oxygen Therapy During Painless Gastros
Gastroscopy is a commonly used, direct, and reliable method for screening and diagnosing digestive tract diseases. However, as an invasive examination, it can cause adverse reactions such as pain, nausea, vomiting, and choking cough in patients. Compared with ordinary gastroscopy, painless gastroscopy offers higher com
| Condition(s) | Hypoxia, Obesity, Gastrostomy |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Gastroscopy is a commonly used, direct, and reliable method for screening and diagnosing digestive tract diseases. However, as an invasive examination, it can cause adverse reactions such as pain, nausea, vomiting, and choking cough in patients. Compared with ordinary gastroscopy, painless gastroscopy offers higher comfort and satisfaction for patients and greater convenience for endoscopists during operation. The most common complication of painless gastroscopy diagnosis and treatment is hypoxia. High-flow nasal cannulala (HFNC) provides a higher oxygen concentration and flow rate than an ordinary nasal catheter. It has the functions of heating and humidifying, which can relieve the pressure on the nasal mucosa cilia, keep the airway unobstructed and moist, and reduce the risk of epistaxi |
| Who can participate | Inclusion Criteria: 1. Patients undergoing painless gastroscopy; 2. Patients with an age greater than 18 years old; 3. American Society of Anesthesiologists (ASA) physical status classification from Grade I to Grade III; 4. Body Mass Index (BMI) greater than 28 kg/m² Exclusion Criteria: 1. Patients with contraindications to endoscopic procedures or those who refuse sedation/anesthesia; 2. Patients allergic to propofol, eggs, soybeans, milk, etc.; 3. Patients with gastrointestinal tract obstruction and gastric emptying disorders; 4. Patients with acute pharyngitis, tonsillitis, and upper respiratory tract infections; 5. Patients in the acute exacerbation stage of respiratory diseases such as asthma, bronchitis, and chronic obstructive pulmonary disease (COPD); 6. Patients with acute arrhyth |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Nanjing First Hospital, Nanjing Medical University |
| Locations | Nanjing, China |
| Start date | 2025-05-14 |
| NCT ID | NCT06966934 |
| Official listing | https://clinicaltrials.gov/study/NCT06966934 |